Use of conjugate vaccines to prevent meningitis caused by Haemophilus influenzae type b or Streptococcus pneumoniae.
Antibodies to the capsular polysaccharides of Haemophilus influenzae type b or Streptococcus pneumoniae protect against meningitis caused by these bacteria. Many of the polysaccharides are poorly immunogenic, especially in infants, but can be turned to highly immunogenic vaccines by covalent conjugation to a protein carrier. On the basis of the good protection observed in several trials, H. influenzae type b conjugates have been accepted for wide use. This experience has also provided direction for the development of new conjugates against infections caused by the most common serotypes of S. pneumoniae. First results from immunogenicity studies of these pneumococcal conjugate vaccines are promising.
Eskola
J
J
National Public Health Institute, Helsinki, Finland.
D001428:Bacterial Vaccines / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D018073:Haemophilus Vaccines / Q000276:immunology; D006801:Humans; D007223:Infant; D008583:Meningitis, Haemophilus / Q000517:prevention & control*; D008586:Meningitis, Pneumococcal / Q000517:prevention & control*; D022242:Pneumococcal Vaccines; D013296:Streptococcus pneumoniae / Q000276:immunology; D018074:Vaccines, Conjugate
D001428:Bacterial Vaccines; D018073:Haemophilus Vaccines; D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate